Movement Alert|Oscar Health Rises 5.08% in Regular Trading, Consecutive Analyst Upgrades Continue to Fuel Rally

Market Focus06-12 03:18

On June 12, Oscar Health rose 5.08% in regular trading, trading at $29.20/share, with turnover of $121 million. The stock has maintained strong upward momentum following consecutive rating upgrades from major investment banks.

On the news front, Barclays upgraded Oscar Health from Equal Weight to Overweight on June 10, raising its target price from $30 to $35, making it the second major bank to upgrade the stock in recent weeks. Earlier, Wells Fargo upgraded the company from Underweight to Equal Weight on June 4, lifting its target price from $11 to $20. Analyst Stephen Baxter cited growing confidence in the ACA market, noting that enrollment and medical cost results have come in better than expected.

Underpinning the upgrades is Oscar Health's strong Q1 performance, with total revenue of $4.65 billion (up 53% YoY), net income of $679 million, and EPS of $2.07 versus consensus of $1.10. Membership reached 3.2 million, up 56% YoY. The company reaffirmed full-year revenue guidance of $18.7-$19.0 billion with significant margin expansion expected.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment